# A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma

> **NCT02099396** · PHASE2,PHASE3 · UNKNOWN · sponsor: **China Association of Osteosarcoma Chemotherapy** · enrollment: 100 (estimated)

## Conditions studied

- Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma

## Interventions

- **DRUG:** Docetaxel+lobaplatin
- **DRUG:** Gemcitabine+lobaplatin

## Key facts

- **NCT ID:** NCT02099396
- **Lead sponsor:** China Association of Osteosarcoma Chemotherapy
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-04
- **Primary completion:** 2016-06
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2014-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02099396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02099396, "A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma". Retrieved via AI Analytics 2026-06-20 from https://api.ai-analytics.org/clinical/NCT02099396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*